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A B S T R A C T
Purpose: To evaluate the efﬁcacy, safety, and tolerability of lacosamide in adults with LGS in the clinical
setting.
Method: The present report is a retrospective, open-label treatment study carried out from June 2013 to
December 2014 at the National Institute of Colombia. Lacosamide was introduced as add-on therapy. All
caregivers were instructed to initiate lacosamide at low doses (25–50 mg) and gradually increasing it
every 2 weeks. The efﬁcacy was evaluated based on the reduction in the rate of each countable type of
seizure. We also evaluated the retention rate for lacosamide as the number of days with lacosamide
during follow-up. The tolerability was evaluated base on account the adverse events.
Results: We found that lacosamide only improves the seizure rate in three out of 19 patients with LGS, in
two of them by more than 50%. The highest seizure reduction rate was observed in the focal and tonic-
clonic seizures. The most commonly reported adverse events were worsening of seizures, aggressiveness
and irritability. Nine patients (47.4%) showed worsening of their behavior during the treatment with
lacosamide.
Conclusion: Lacosamide can exacerbate both, the tonic and astatic seizures, and the encephalopathy
associated with this epileptic syndrome. However, it is interesting to consider the likelihood of
suppression of generalized tonic-clonic and focal seizures. That is why; lacosamide could be an option
after carefully balancing risks and beneﬁts in each individual case.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Unlike to Lennox–Gastaut syndrome (LGS) in childhood, which
has been extensity studied [1], less is known about the
electroclinical features and treatment of LGS in adult life. Such
syndrome is characterized by multiple, drug-resistant seizure
types and progressive mental deterioration after epilepsy onset
[2]. Nevertheless, some atypical features have been described in
adult patients with this syndrome [2,3]. Because of that, the choice
of the antiepileptic medication could be different.* Corresponding author at: Instituto Neurolo´gico de Colombia, Medellı´n,
Antioquia, Cll 55 # 46-36, Colombia. Tel.: +57(4) 5766666x2204;
fax: +57 (4) 5133016 (O).
E-mail address: rene.andrade@neurologico.org.co (R. Andrade-Machado).
http://dx.doi.org/10.1016/j.seizure.2015.10.009
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reLacosamide (LAC) is one of the latest anti-epileptic drugs (AEDs)
available on the market [4]. Potential mechanisms of action
include the enhancement of slow inactivation of voltage-gated
sodium channels, which leads to an increased proportion of
sodium channels unavailable for depolarization [4]. LAC has a
favorable proﬁle as it is completely absorbed after oral adminis-
tration exhibiting 15% of protein binding [4,5]. The drug has not
been shown to induce or inhibit CYP enzymes in preclinical/clinical
studies examining speciﬁc CYP substrates [4]. Although double
blind placebo-controlled clinical trials demonstrated the efﬁcacy
of LAC in adults with partial onset seizures [6–9], the efﬁcacy and
tolerability of LAC in the treatment of generalized epileptic
syndromes like LGS in childhood and adult patients have yet to be
clariﬁed.
Grosso et al. reported a retrospective, multicenter study, which
was conducted to evaluate the efﬁcacy and safety of LAC inserved.
R. Andrade-Machado et al. / Seizure 33 (2015) 81–8782children affected by LGS [10]. The authors concluded that a third of
the children with LGS responded to LAC as an add-on therapy, thus
they suggested that LAC might be effective and represent of a
possible therapeutic option in children affected by LGS [10]. This
study was criticized because of some methodological issues; thus,
some authors suggested to use LAC cautiously in children with LGS.
To review the principal criticism/comments to this study, we
recommend to read two letters to the editor that were published
by Andrade-Machado et al. and Italiano et al. last year in Acta
Neurological Scandinavica [11,12].
Studies of the use of LAC in adult patients with LGS are scarce
and limited to case reports. Cuzzola et al. published in 2010 three
adult cases with LGS who developed seizure worsening after
introducing LAC as an add-on therapy [13]. Andrade-Machado
et al. in 2012, reported a tonic status epilepticus induced by LAC in
an adult male with LGS; in that report the authors also showed a
worsening in one of the characteristic electrographic patterns of
this epileptic syndrome, generalized paroxysmal fast activity
(GPFA) [14].
Considering the limitations of the above-mentioned case
reports and the study carried out by Grosso et al. in children,
we conducted a retrospectively analysis of 19 adult patients with
LGS in which LAC was used as an add-on therapy to improve
seizure control as a desperate measure after multiple antiepileptic
drugs, corpus callosotomy surgery or vagal nerve stimulation
(VNS) failures. We aimed to observe the efﬁcacy, safety, and
tolerability of LAC in adults with LGS in the clinical setting.
2. Patients and methods
This is a retrospective, open-label treatment study carried out
from June 2013 to December 2014 at the National Institute of
Colombia. All patients were recruited from our outpatient facilities
(ﬁve in the case of adults with epilepsy). In our institution all the
patients who require a video-EEG recording are evaluated in our
neurophysiology unit. A total of 35 adults with LGS have been
diagnosed in our institution since 2012. Nineteen of them have
been treated with LAC as add on therapy. In those patients, LAC was
introduced as an add-on therapy because all previous therapies
have failed but not for research purposes. The institutional ethical
committee approved the present study. Written informed consent
before LAC was added to their treatment was not requested.
2.1. Inclusion criteria:
(i) Age above 16 years; (ii) LGS refractory to at least three
previous antiepileptic drugs (AEDs), alone or in combination; (iii)
exhibiting at least four seizures per month during the 3 months
before LAC was introduced; (iv) use of at least one other AED; (v) to
have a 24 h video-electroencephalographic monitoring in the
3 months before the introduction of LAC.
All seizures were classiﬁed according to the International
League Against Epilepsy Revised Classiﬁcation of Seizures, while
diagnostic criteria for LGS were based on the following criteria: (i)
polymorphous seizures including tonic–axial, and at least one of
the following seizure types should be present: astatic, atonic or
atypical absences. The presence of myoclonic, GTCS or partial
seizures were not a cause for exclusion; (ii) EEG abnormal EEG
background activity, slow spike-waves <3 Hz and, often, multifo-
cal abnormalities and bursts of 10 Hz fast rhythms during sleep;
(iii) in general, mental retardation.
The diagnosis of LGS in all patients included in the study was
corroborated with a 24 h video-electrographic monitoring TV
recording. All traces were evaluated by two neurologist (RAM and
JFAR) with special expertise in the diagnosed of electroclinical
epileptic syndromes.All patients underwent brain 1.5 T magnetic resonance imaging
(MRI), biochemical analyses, chromosomal investigations and
screening for metabolic diseases. Also all patients had a formal
neuropsychological evaluation prior to the use of lacosamide.
2.2. Information about how the study data was gathered:
The study began in June 2013 and ﬁnished in December 2014
(18 months of follow-up). In our institution each patient visits our
outpatient facility every 3 months. To facilitate the understanding
of the present study, we considered the entry to the study when a
patient was instructed to receive LAC. All caregivers were
instructed to initiate lacosamide at low doses (25–50 mg per
day with gradually increasing the dose every 2 weeks until
reaching 200 mg per day. The present study is retrospective and
represents the daily clinical practice; the doses reported were
those reported in the medical records according to the prescription
made by the neurologist in the outpatient clinical setting. During
treatment, general and neurological examinations were performed
every 3 months in all patients. LAC serum levels were not
measured because of lack of availability in our laboratories.
According to the institution protocols each caregiver has a
seizure calendar to annotate the frequency, semiology and
precipitants of seizures and the possible side effects of the
medications. This calendar was review by the Neurologist in each
visit and registered in medical records. As all patients had a
calendar, the basal seizure frequency was analyzed base on the
frequency per months during the 3 months before LAC was
introduced.
In order to improve the care of the patients, our institution has an
epilepsy program carried with a multidisciplinary group including
social worker, general physicians, nurses, neurologists and epilep-
tologists. During each visit, the family/caregivers (in cases of
patients with severe disabilities) were questioned about the
patient’s behavior, learning and independence, needing of psychia-
trics or pedagogic accompanying and previous admissions to other
institutions. All information regarding the above-mentioned
aspects, are then registered in the patient medical record.
Complete peripheral blood counts, urinary analysis, blood
creatinine and alanine and aspartate aminotransferase levels were
also monitored, and when possible, blood levels of concomitant
AEDs.
Treatment was discontinued when the neurologist considered
that it was not effective or in cases in which seizure aggravation
was suspected. As this study has a retrospective design, concomi-
tant drug regimen could be changed during the retrospective
baseline phase. Review of the medial records showed the following
changes in the concomitant AEDs: Vigabatrin was discontinued in
two patients after 6 months of follow-up and Valproate in two
patients after 3 months of follow-up. The remaining AEDs were not
changed.
2.3. Evaluation of efﬁcacy:
Efﬁcacy was evaluated based on the reduction in the rate of
each countable type of seizure. The percentages of patients with
more than 50% and less than 50% but more than 25% reduction in
seizure frequency, were also assessed, and both were deﬁned as
responder. We also evaluated the difference between seizure
frequencies before and after LAC was introduced. Treatment was
considered as not effective when the doses of 200–300 mg per day
were reached and no seizure improvement was reported. In
patients in whom LAC was not dropped out because of adverse
effects or seizures aggravation, the difference between the seizure
frequency before and after LAC was introduced, was calculated
after 18 months of follow-up.
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absences and myoclonic seizures, we did not provide data on the
efﬁcacy of lacosamide for this type of seizures.
We also evaluated the retention rate for lacosamide as the
number of days with LAC during the follow-up.
2.4. Evaluation of tolerability:
Efﬁcacy was evaluated based on the reduction in the rate of
each countable type of seizure. The percentages of patients with
more than 50% and less than 50% but more than 25% reduction in
seizure frequency, were also assessed, and both were deﬁned as
responders. We also evaluated the difference between seizure
frequencies before and after LAC was introduced. Treatment was
considered as not effective when the doses of 200–300 mg per day
were reached and no seizure improvement was reported. In
patients in whom LAC was not dropped out because of adverse
effects or seizures aggravation, the difference between the seizure
frequency before and after LAC was introduced, was calculated
after 18 months of follow-up.
Due to the difﬁculty in determining the frequency of atypical
absences and myoclonic seizures, we did not provide data on the
efﬁcacy of lacosamide for this type of seizures.
We also evaluated the retention rate for lacosamide as the
number of days with LAC during the follow-up.
2.5. Evaluation of tolerability:
The presence of adverse events was obtained retrospectively
from medical records and from the parents/caregivers, by
telephone conversation carried out by the authors of this
investigation at the moment of database completion. Information
obtained from medical records included: 1. Vital signs, general
and neurological examination. 2. Adverse events reported by the
Epileptologists. 3. Laboratory values (blood and urinary tests).
The data evaluated were obtained from each visit during the last
18 months. By telephone conversation each parent/caregivers was
requested to respond the following question: during or after
treatment with LAC, have you felt that your child has suffered or
reported one of the following symptoms?: dizziness, sedation,
headache, tremor, ataxia, rash, diplopia, fatigue, weight gain,
depression, worsening of seizures, agitation, dysarthria, insomnia,
vomiting, withdrawal because of side effects, or something else
that you consider to mention. All the reported symptoms were
taking into account.
Possible effects on behavior, and the possibility of inducing or
aggravating typical seizures in LGS (paradoxical reaction) as it has
been previously reported, was also evaluated.
Effects of LAC on behavior were evaluated following a Likert’s
scale constructed for the purposes of the present study:
2.6. Behavior before/after LAC introduction:
Patient with total independence for daily activities (dressing,
bathing and eating without assistance), without psychiatric
medications and schooled = 0; patient with total independence
for daily activities (dressing, bathing and eating without
assistance), is on psychiatric medications to control his/her
behavior and is schooled = 1; patient with total independence for
daily activities (dressing, bathing and eating without assistance),
is on psychiatric medications to control his/her behavior and is
not schooled = 2; patient with total dependence for daily
activities, is on psychiatric medications to control his/her
behavior and is not schooled = 3; patient with total dependence
for daily activities, is on psychiatric medications but it is not
enough to control his/her behavior, is not schooled but does notrequire custody = 4; patient who require custody to avoid
damage to him/herself, and the psychiatric medication does
not control his/her behavior.
The data required for behavior scale was obtained from the
medical record and telephone conversations with the parents at
the moment of database completion for the study.
The Institutional Review Board and ethical committee approved
this investigation.
2.7. Statistical analysis:
Data was processed with STATISTIC software version 6.0 and
presented in tables and graphics. All data are presented as
frequencies and percentages. For comparison of quantitatively
non-continuous variables (before/after rank ordering of observa-
tions), the Wilcoxon matched pair test was used. For comparison of
qualitative variables chi-square test was used. Due to the small
sample analyzed, to evaluate whether the etiology inﬂuence on
therapeutic response, the symptomatic and cryptogenic subgroups
were compared considering whether or not there was seizure
improvement or the likelihood of worsening of seizures after
treatment, according to each type of seizure. For this purpose chi-
square test was used. The results were considered statistically
signiﬁcant when p value was <0.05.
3. Results
We included 19 patients (12 males, 7 females), aged between
18 and 61 years (mean 27.1  14.2), who were under LAC as an add-
on therapy. Nineteen patients (100%) had tonic seizures, 18 (94.7%)
had astatic and atypical absences seizures, 16 (84.2%) had atonic
seizures, and 3 (15.8%) had focal seizures. Seven patients were
diagnosed as cryptogenic and 12 as symptomatic LGS. All patients had
mental retardation. All (19/19) had paroxysmal fast activity and
generalized <3 Hz SW (100%), and focal paroxysmal discharges were
documented in 12 of 19 patients (Table 1).
Mean age at the time of seizure onset was 4.6 (range: 1–15
years). Mean duration of epilepsy was 22.5 years (range: 8–59).
Seizure frequency during baseline phase was the following: tonic
seizures >30/day (nine patients); 30/day (10 patients); astatic
seizures >10/day (four out of 18 patients); tonic-clonic seizures
<10/day (15 out of 19 patients); focal seizures <10/day (three out
of 19 patients).
Before the LAC trial, patients had been treated with 1–4 AEDs.
Nine out of 19 patients (47.4%) were treated with two AEDs. The
most commonly used concomitant antiepileptic comedication was
levetiracetam (14 patients). Four patients had vagus nerve
stimulation therapy prior to starting LAC and in seven callosotomy
was performed before the introduction of LAC. LAC was adminis-
tered in two equal daily doses: median of initial dose of 25 mg
(range 25–50). The range of maximum doses was between 50 mg
and 300 mg, with a median of 200 mg.
The clinical efﬁcacy according to seizure type and etiology is
summarized in Table 2. LAC reduced the seizure frequency by more
than 50% in two (10.5%) patients responder and by less than 50% in
other one patient (5.3%). In 16 (78.9%) patients an increased in
tonic seizure frequency was documented, and 3 out of 19 (15.8%)
reported no changes in tonic seizures during treatment. Seven of
18 patients reported an increase in astatic seizures. The frequency
of tonic-clonic seizures was not increased during LAC treatment.
The highest seizure reduction rate was observed in the focal and
tonic-clonic seizures. We did not found a signiﬁcant statistical
association between the etiology (symptomatic or cryptogenic)
and the reduction of frequency of atonic, tonic and tonic-clonic
seizures (p > 0.05), number of patients with tonic status or
repetitive cluster of tonic seizures (p > 0.05) and number of
Table 1
Clinical ﬁndings of patients.
Characteristics Value
Age (years) mean  SD range 27.1  14.2 (18–61)
Sex M/F 12 (63.2)/7 (36.8)
Age at seizure onset (years) mean  SD range 4.6  2.7 (1–15)
Seizure types, n (%)
Tonic 19 (100)
Atonic 16 (84.2)
Atypical absences 18 (94.7)
Astatic 18 (94.7)
TCS 15 (78.9)
Myoclonic seizures 5 (26.3)
Focal seizures 3 (15.8)
Etiology classiﬁcation, n (%)
Symptomatic 7 (36.8)
Cryptogenic 12 (63.2)
Mental retardation 19 (100)
Epilepsy duration (years) mean  SD range 22.5  14.6 (8–59)
Electrographic features
<3 Hz SW 19 (100)
PFA 19 (100)
Focal discharges 12 (63.5)
Frequency of seizures – 3 months before lacosamide
Tonic seizures/month
>30 9 (47.7)
20–30 4 (21.1)
10–20 2 (10.1)
<10 4 (21.1)
Astatic seizures/month
10–20 4 (21.1)
<10 14 (73.8)
Tonic-clonic seizures/month
<10 15 (78.9)
Focal motor seizures/month
<5 3 (15.8)
Number of AEDs when LAC was initiated, n (%)
1 4 (21.1)
2 9 (47.4)
3 6 (35.6)
4 0 (0)
Concomitant AEDs, n (%)
VPA 9 (47.4)
TPM 8 (42.1)
LEV 14 (73.7)
CLB 4 (21.1)
VGB 2 (10.5)
LTG 3 (15.8)
Previous callosotomy 4 (21.1)
Previous VNS 7 (36.8)
Previous VNS/Callosotomy 4 (21.1)
Lacosamide
Initial dose (range) 25 (25–50)
Maximum dose (range) 200 (50–300)
Number of days with lacosamide (range) 90 (25–540)
M: male; F: female; AED: antiepileptic drug; VPA: valproic acid; TPM: topiramate;
LEV: levetiracetam; CLB: clobazam; OXC: oxcarbazepine; PHT: phenytoin; VGB:
vigabatrin; LAC: lacosamide; PFA: paroxysmal fast activity; LTG: lamotrigine; TCS:
tonic-clonic seizures.
Table 2
Efﬁcacy of Lacosamide in children with symptomatic or cryptogenic Lennox–
Gastaut syndrome (variation in countable seizures).
Responding rate Number of
patients
N = 19
Number of
patients with
symptomatic LGS
N = 7
Number of
patients with
cryptogenic LGS
N = 12
Patients? responding rate Symptomatic N = 7 Cryptogenic N = 12
100% 0 (0) 0 (0) 0 (0)
>50% < 100 2 (10.5) 2 (10.5) 0 (0)
<50% 1 (5.3) 1 (5.3) 0 (0)
Tonic seizures N = 19 Symptomatic N = 7 Cryptogenic N = 12
100% 0 (0) 0 (0) 0 (0)
>50% < 100 1 (5.3) 1 (14.3) 0 (0)
<50% 0 (0) 0 (0) 0 (0)
Unchanged 3 (15.8) 1 (14.3) 2 (16.7)
Increased 16 (78.9) 5 (71.4) 10 (83.3)
Percentage in seizure variation
Astatic seizures N = 18 Symptomatic N = 6 Cryptogenic N = 12
100% 0 (0) 0 (0) 0 (0)
>50% < 100% 0 (0) 0 (0) 0 (0)
<50% 0 (0) 0 (0) 0 (0)
Unchanged 12 (66.6) 4 (66.6) 8 (66.7)
Increased 7 (38.8) 2 (33.4) 4 (33.3)
Percentage in seizure variation
Tonic-clonic seizures N = 15 Symptomatic N = 7 Cryptogenic N = 8
100% 0 (0) 0 (0) 0 (0)
>50% < 100 11 (73.3) 5 (71.4) 6 (75)
<50% 2 (13.3) 2 (28.6) 0 (0)
Unchanged 2 (13.3) 0 (0) 2 (25)
Increased 0 (0) 0 (0) 0 (0)
Focal seizures N = 3
100% 3 (100) 3 (100) 0 (0)
Symptomatic N = 4 Cryptogenic N = 5
N = 9 (47.3%)y/s 7 (36.8)/2 (10.5) 3 (42.9)/1 (14.3) 3 (25)/2 (16.7)
Symptomatic N = 4 Cryptogenic N = 5¥
N = 9 (47.3%) 9 (100) 3(75)/1(25) 3 (60)/2 (40)
Symptomatic N = 4 Cryptogenic N = 56¼
N = 9 (47.3%) 9 (100) 3(75)/1(25) 3 (60)/2 (40)
% are referred to the total of the columns. mean p > 0.05, mean p = 0.01.
y/s Number (%) of patients with tonic status/or repetitive cluster of tonic seizures
after introduction of lacosamide.
¥ Number (%) of patients who discontinued LAC due to status or cluster of tonic
seizures.
6¼ Number (%) of patients that returned to basal seizure rate after lacosamide
discontinuation.
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tonic seizures. Nevertheless, the response rate for all seizure types
was associated with the etiology (p < 0.05).
The median dose required for clinical response was 100 mg for
focal (range: 100–250 mg) and tonic-clonic (range: 100–250 mg)
seizures. Tonic and astatic seizures worsened with doses of 75 mg
(50–100 mg) and did not improve with median doses of 200 mg
(Table 3).3.1. Safety
LAC treatment was associated with worsening of behavioral
problems (Table 4). After introduction of LAC, nine out 19 patients
(47.3%) presented worsening in the behavior scales. The median in
Likert scale before and after LAC introduction remained stable,
nevertheless, the lower and upper quartiles increased from 0 to 2
(lower quartile) and from 3 to 4 (upper quartile). This effect reach
statistical signiﬁcance (Wilcoxon Matched pair test p = 0.007).
Nine patients (47.7%) reported adverse side effects during
treatment with LAC. The most commonly reported adverse events
were worsening of seizures, aggressiveness, and irritability, each
one in nine patients (47.7%). Somnolence was the second most
common reported side effect (31.6%). LAC discontinuation led to
reduction to baseline seizure frequency in all of them. There were
no signiﬁcant laboratory anomalies in liver, renal or hematologic
functions (Table 5).
It was interesting to ﬁnd that all patients for whom seizures
improved by more than 25% were male, with symptomatic LGS
with focal discharges and lesional MRI ﬁndings. All of them were
on polytherapy regimen with clobazam (Table 6).
Table 3
Lacosamide dose according to responding, worsening or unchanged seizure rate.
Lacosamide doses mg Median Minimum Maximum
Tonic seizures N = 19
Responding 200 200 200
Worsening 75 50 100
Unchanged 200 200 250
Astatic seizures N = 18
Worsening 75 50 100
Unchanged 200 150 300
Tonic-clonic seizures N = 15
Responding 100 100 250
Unchanged 150 100 300
Focal seizures N = 3
Responding 100 150 250
Patients with tonic status or repetitive
cluster of tonic seizures after
introduction of Lacosamide
75 50 100
Table 4
Behavior analysis before and after introduction of Lacosamide.
Behavior analysis (Likert scale) Score variation on Likert scales after
Lacosamide introduction: patients (%)yyy
0 variation 10 (52.6)
Total of patients with worsening
on the behavior scale
9 (47.4)
Increased 1 point 6 (31.6)
Increased 2 points 1 (5.3)
Increased 3 points 2 (10.5)
yyy Median (range) [lower quartile; upper quartile] Wilcoxon matched pair test, p
value [before/after lacosamide]: 2 (0–4) [0;3]/2 (0–4) [2;4]; p = 0.007.
Table 5
Side effects reported after introduction of Lacosamide.
Side effects N = 9 Number (%)
Somnolence 6 (31.6)
Aggressiveness 9 (47.7)
Irritability 9 (47.7)
Dizziness 2 (10.5)
Vomiting 3 (15.8)
Euphoria 2 (10.5)
Increased number of seizures 9 (47.7)
Number of patients in whom improvement was noted
after reduction of dose
6 (31.6)
Discontinuation of Lacosamide due to side effects other
than seizure aggravation
(0)
Lacosamide discontinuation led to reduction of baseline
seizure frequency N = 9
9 (100)
Laboratory anomalies 0 (0)
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LAC has a novel mechanism of action that seems to be different
from the existing AEDs in that it selectively enhances the slow
inactivation of voltage-gated sodium channels. Also, LAC reduces
the ability of (epileptic) neurons to sustain prolonged ﬁring bursts
by regulating the long-term availability of voltage-gated sodiumTable 6
Analysis of patients with a responding rate by more than 25%.
Cases Age Sex Etiology Focal seizures PFA/3 Hz SW Focal 
1 18 M S Yes Yes Yes 
2 23 M S Yes Yes Yes 
3 25 M S Yes Yes Yes 
S, means symptomatic; M, male; SW generalized spikes and waves; ED epileptiform dchannels. In addition, experimental data suggests a synergic effect
when used in combination with other AEDs. The aforementioned
data led us to expect a beneﬁcial effect of LAC as an add-on
treatment.
Thus, LAC has been approved by the licensing authorities in the
United States and in the European Union as an add-on treatment of
partial seizures in patients with 16 years of age or older. Anecdotal
reports on the efﬁcacy of LAC in LGS have been published
[10,13,14].
The present study is to our knowledge the ﬁrst study that
describes the follow-up of adult patients with Lennox Gastaut
Syndrome treated with Lacosamide.
In an extended review on pubmed and medline only a few
reports of LAC treatment in LGS were found. The results reported
are contradictory. Cuzzola et al. [13] reported a paradoxical
reaction to LAC in three adult patients with LGS. All of them
showed an increased frequency of tonic seizures with tonic status
occurring in one of them. All patients returned to their previous
clinical condition after drug withdrawal. Andrade-Machado et al.
[14] reported a 20-year-old male affected by LGS who showed a
clinical exacerbation of tonic seizures after starting LAC. By
contrast, Rastogi and Ng [15] showed that LAC was effective in two
patients with LGS with more than 90% seizure reduction.
Moreover, Casas-Ferna´ndez et al. [16] recently described another
two patients with LGS who were responsive in terms of seizure
control to add-on LAC therapy.
Grosso et al. reported the follow-up of 18 children with LGS.
They found a responsive rate of about 30% [10]. The paper
published by Grosso et al. received many criticisms. The authors
considered the diagnosis of Lennox–Gastaut syndrome in patients
without tonic seizures, (4 of 18 (22.2%) of patients). In these cases
the diagnosis was based on the accepted ILAE criteria for the
classiﬁcation of seizures and epileptic seizures published in 1989
[17]. Nevertheless, it is well known that tonic seizures should be a
prerequisite for the diagnosis of LGS [1]. In that scenario, it is
possible that 22.2% of patients reported in this study suffered from
multifocal or focal epilepsy. This could be one reason for higher
responding rate reported in the aforementioned study, due to the
efﬁcacy previously documented for LAC in these epileptic
syndromes [18]. It is concordant with our results that showed a
100% of responding rate for focal seizures in patients with focal
epileptiform discharges and a lesional MRI. Maybe these patients
have been suffering from LGS with focal epilepsy, due to the ﬁnding
of focal discharges, focal lesion on MRI and the presence of focal
seizures. Perhaps many patients with LGS with focal ﬁnding in MRI
and focal seizures could beneﬁt from an add-on regimen of LAC.
The sub-analysis done with the responding patients who
showed focal EEG ﬁndings, led us to recommend further studies
focused in the possible positive pharmacodynamic interaction
between LAC and clobazam. These features have not been reported
previously and it should be evaluated in future prospective studies.
On the other hand, as was reported by Andrade-Machado et al.
[14], the aggravation of LGS is not only due to the effect of LAC on
clinical seizures, but also, because of the worsening of the
encephalopathic electrographic patterns (fast rhythms). It is also
known that most of the tonic seizures in LGS are subtle and onlyED MRI ﬁndings Other treatment Concomitants AEDS
Posterior quadrant gliosis VNS LEV + CLB
FCD Callosotomy LEV  CLB
Frontal gliosis VNS and
callosotomy
VPA + VGB + CLB
ischarges; PFA: paroxysmal fast activity; FCD focal cortical dysplasia.
R. Andrade-Machado et al. / Seizure 33 (2015) 81–8786seen in polygraphic video-EEG recordings [1]. In the study of
Grosso et al. [10], the seizure type and frequency were registered
by parents and/or nursing staff and reviewed at each follow-up
visit. They never mentioned the use of video-EEG recording as a
tool for determining a potential electrographic aggravation caused
by LAC. Therefore, most of subtle tonic seizures and the rate of fast
rhythms before and after treatment could not be recognized. That
is why, in our opinion, the efﬁcacy and effectiveness of LAC was not
correctly evaluated. The most important aspect is that subtle tonic
seizures and fast rhythms have been associated with a cognitive
decline in patients with an epileptic encephalopathy [1]. According
to this, we did not evaluate our patients with polygraphic studies
during the follow-up, but the worsening of behavior documented
in the present study could be explained at least by worsening in the
encephalopathy associated with this epileptic syndrome second-
ary to the use of LAC [14]. The aggravation of seizures and behavior
cannot be explained by drug-to-drug interaction because the
administration of LAC to extensive or poor metabolizers of the
cytochrome P 450 subsystem 2C19 has showed that there is no
relevant effect on metabolism and elimination of LAC by this
system. In addition, a recent pharmacokinetic study excluded an
interaction of clinical signiﬁcance between LAC and other AEDs
[19,20]. Therefore, we can exclude LAC-induced aggravation of LGS
due to pharmacokinetic interactions with other AEDs.
The incidence of side effects reported with LAC treatment
varied from 29% to 61%. Our range of side effects is similar to those
reported previously in the literature [4,21,22]. Most adverse effects
seen with LAC in adults are dose-related and are reversible upon
discontinuation or dose reduction. In adults, LAC doses up to
400 mg/day may be well tolerated [4]. The range dose of LAC in our
study was (50–300)/day, with an incidence of adverse events of
47.4% [21,22].
Dosage reduction was necessary in all patients with worsening
seizures and in all of them it was followed by a seizure frequency
reduction to the baseline rate. The percentage of patients with
increased seizure frequency (47.4%) found in the present study is
greater than what was the reported by Grosso et al. study, but is
congruent with the previously reported effects in this epileptic
syndrome by us and Cuzzola et al. [13,14]. A diagnosis of
paradoxical reaction can be made in these patients due to the
fact that all of them returned to baseline seizure rate after LAC
discontinuation.
Despite of possible worsening of behavior, tonic and astatic
seizure frequency, it is interesting the combination of suppression
of generalized tonic-clonic and focal seizures, induced by LAC,
found in the present study.
The electroclinical features of an epileptic syndrome can be
considered as reﬂecting the speciﬁc cerebral networks being
recruited. In this context, a neural network comprises anatomically
and functionally connected cortical and subcortical brain struc-
tures, where activity in any one part of the network, may affect
activity in all the others. Simultaneous measurement of EEG and
fMRI has demonstrated two different patterns of cortico-subcorti-
cal activation in patients with LGS [23,24]. GPFA, the electro-
graphic pattern associated with tonic seizures, has been associated
with activation across broad areas of cortex, but appears to spare
the primary cortices. GPFA shows increased BOLD signal in a
number of subcortical structures including the thalamus, basal
ganglia, and brainstem, all known to have broad connections to the
‘‘association cortices’’. This observation of activation in many areas
associated with association cortex and its subcortical system, but
excluding primary cortex, has led investigators to call the network
activation ‘‘diffuse association network activation’’ (DANA). A
different scenario is seeing in some patients with LGS, even though
the EEG appeared to be generalized, the BOLD signal characteristics
of discharges had lateralized features or even suggestions offocality. In these cases, the above-mentioned ﬁndings were
concordant with the EEG or structural ﬁndings. This suggests that
cortical lesions can be activated along with this diffuse activation
of the association networks (DANA), possibly co-opting it as an
epileptic network or at least engaging this system in the epileptic
activity in LGS. Thus, focal ictal onset zone can activate secondarily
this DANA, resulting in the same electroclinical phenotype (LGS).
EEG-fMRI maps may be showing both the DANA and an
epileptogenic focus that is likely to drive the network instability.
These notions have been also supportive by SPECT and PET studies
[24].
We should analyze our results in face of this ‘‘secondary
network disorder’’. The improvement in seizure rate and focal
seizures in our cohort can be explained by these hypotheses,
because LAC is very effective in control of partial onset seizures,
according to double blind placebo-controlled clinical trials [6–9].
Thus, in this subgroup of patients, LAC could inhibit an
epileptogenic focus and therefore, prevent seizures arise from it.
Our study have some weaknesses that make difﬁcult to
extrapolate it to other scenarios, these include: ﬁrst, the
retrospective nature and the small series of patients. However,
the study design reﬂects daily clinical practice and provides a more
realistic view of the use of LAC in adults. The size of our population
was not so large to able us to draw more deﬁnite conclusions and
therefore, we recommend further clinical trials to validate or to
refuse our data. The study was carried out in a tertiary center that
did not necessarily reﬂect all scenarios, but as we are treating a
severe epileptic syndrome, almost all patients with LGS are
actually treated in a highly specialized center for treatment of
these epileptic syndromes. However, caution is still necessary
when the drug is used in adults with LGS, because our preliminary
observations suggest that LAC might exacerbate tonic and astatic
seizures and also the encephalopathy associated with this epileptic
syndrome. Thus, we do not recommend the use of lacosamide in
adults with LGS.
5. Conclusions
Lacosamide may not be effective to treat patients with adult
Lennox Gastaut syndrome as it can exacerbate tonic and astatic
seizures, and the encephalopathy associated with this epileptic
syndrome. It is interesting to consider the likelihood of suppression
of generalized tonic-clonic and focal seizures, due to the fact that
these seizures might be the most disabling seizure types in some
adults with LGS. That is why; LAC could be an option after carefully
balancing risks and beneﬁts in each individual case.
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